C4 Therapeutics/$CCCC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About C4 Therapeutics
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
Ticker
$CCCC
Sector
Primary listing
Employees
104
Headquarters
Website
C4 Therapeutics Metrics
BasicAdvanced
$471m
-
-$1.07
2.93
-
Price and volume
Market cap
$471m
Beta
2.93
52-week high
$4.60
52-week low
$1.40
Average daily volume
3m
Financial strength
Current ratio
9.005
Quick ratio
8.755
Long term debt to equity
22.167
Total debt to equity
24.951
Profitability
EBITDA (TTM)
-101.203
Gross margin (TTM)
78.34%
Net profit margin (TTM)
-297.76%
Operating margin (TTM)
-295.77%
Effective tax rate (TTM)
-0.12%
Revenue per employee (TTM)
$340,000
Management effectiveness
Return on assets (TTM)
-19.88%
Return on equity (TTM)
-48.35%
Valuation
Price to revenue (TTM)
11.817
Price to book
1.89
Price to tangible book (TTM)
1.89
Price to free cash flow (TTM)
-4.29
Free cash flow yield (TTM)
-23.31%
Free cash flow per share (TTM)
-0.993
Growth
Revenue change (TTM)
-12.37%
Earnings per share change (TTM)
-27.28%
3-year revenue growth (CAGR)
8.62%
3-year earnings per share growth (CAGR)
-26.32%
What the Analysts think about C4 Therapeutics
Analyst ratings (Buy, Hold, Sell) for C4 Therapeutics stock.
C4 Therapeutics Financial Performance
Revenues and expenses
C4 Therapeutics Earnings Performance
Company profitability
C4 Therapeutics News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs